Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05666960 · ClinicalTrials.gov registry record · Phase 1
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
A Phase 1 study of Ulcerative Colitis and Ulcerative Colitis Chronic, sponsored by Rise Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT05666960 is a Phase 1 study of Ulcerative Colitis and Ulcerative Colitis Chronic that is actively recruiting participants, run by Rise Therapeutics. The registered enrollment target is 36 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT05666960, a Phase 1 study of Ulcerative Colitis and Ulcerative Colitis Chronic, is actively recruiting participants, sponsored by Rise Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate ulcerative colitis. Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and physician scored measures of their colitis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-3750) on fecal levels will also be measured.
Conditions Studied
Interventions
- DRUG R-3750
Study Locations (4)
Florida
- AP Medical Research LLC - Miami
- Edward Jenner Research Group, LLC - Plantation
California
- Amicis Research Center - Valencia
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05666960
The ClinicalTrials.gov registry entry for NCT05666960 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The listed sponsor is Rise Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which R-3750 is the first listed.
NCT05666960 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05666960 about?
NCT05666960 is a clinical study titled "R-3750 in Patients With Mild to Moderate Ulcerative Colitis". The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate ulcerative colitis. Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and physician scored measures of their colitis. Blood and ...
What is the current status of trial NCT05666960?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-02-27. Estimated completion is 2026-10.
What conditions does trial NCT05666960 study?
This clinical trial studies the following conditions: Ulcerative Colitis, Ulcerative Colitis Chronic, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Mild.
What interventions are being tested in trial NCT05666960?
The interventions under investigation include: R-3750 (DRUG).
Who is sponsoring clinical trial NCT05666960?
This trial is sponsored by Rise Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05666960 being conducted?
This trial has 4 study locations across California, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
RECRUITING · Phase 1
-
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
RECRUITING · Phase 1
-
CP101 for the Treatment of Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Angiographic Delivery of AD-MSC for Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
COMPLETED · Phase 1
-
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.